GlassScriptPhysician profile
Daria Abolghasemi
NPI 1265847636
$2,246.58
in general payments reported to CMS, 2019-2025
10 companies · $2,095 in 2025
The $2,095 reported for 2025 was more than what 82% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2025: $2,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114 · Travel and Lodging: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.69 |
| Travel and Lodging | $981.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $1,549.93 | 2025 | |
| Stryker Corporation | $158.19 | 2025 | Spy-Phi System, Molli |
| Genentech USA, INC. | $132.71 | 2019 | |
| Kerecis Limited | $122.05 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Merck Sharp & Dohme LLC | $121.80 | 2025 | Keytruda, Lynparza |
| Dilon Technologies, INC. | $58.70 | 2025 | Hemoblast Bellows |
| Hologic Sales and Service, LLC | $34.11 | 2025 | Magtrace, Magseed |
| Impedimed, INC. | $33.72 | 2025 | |
| Avanos Medical | $19.10 | 2019 | |
| Geron Corporation | $16.27 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daria Abolghasemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.